Need for awareness and immunization against Respiratory Syncytial Virus (RSV) in India
RSV, often mistaken for a mild seasonal cold, accounts for ~ 3.6 million hospitalizations and ~ 100,000 deaths in children under five each year globally. India, with the largest birth cohort of ~ 25 million newborns annually, contributes significantly to this burden. The impact is particularly severe during the country's monsoon and early winter months, when neonatal ICUs experience a surge in admissions. Alarmingly, even healthy, full-term infants across all socio-economic backgrounds often require oxygen or ventilator support due to RSV-related complications. Therefore, raising awareness among parents and healthcare professionals about available preventive measures is critical to reducing the disease's toll on young lives.
Dr. Vasant M. Khalatkar, Current National President, Indian Academy of Pediatrics (IAP), said 'RSV remains a significant threat to infant health, and while hygiene measures like handwashing are essential, they're often not enough—especially for babies under one year. With the recent World Health Organization (WHO) recommendation for long-acting monoclonal antibodies (mAb) and India enabling access to these solutions, we now have vital tools to protect our youngest. Palivizumab has been available for high-risk infants, offering protection through monthly dosing during the RSV season. Now, with the arrival of Nirsevimab—a single-dose, long-acting antibody that provides season-long protection—we're seeing a major advancement. Administered shortly after birth or during routine follow-ups, these preventive options can greatly reduce RSV-related hospitalizations and shield infants from serious complications like bronchiolitis and pneumonia. Prevention, timely awareness, and parental engagement are critical to reducing RSV's impact across India.'
Dr. Cesar Mascarenas, Head of Medical International Region, Sanofi, commented 'We have long been working to close critical gaps in prevention by advancing science-driven solutions that align with evolving global recommendations, including those from the WHO. Addressing RSV burden in India with advanced preventive care is the need of the hour. Strengthening awareness, improving access to protective interventions, and enabling timely immunization are essential steps in reducing the impact of RSV and safeguarding the health of future generations.'
Dr. Bhavesh Kotak, Head, Medical Affairs, Dr. Reddy's, added 'India bears a significant share of the global RSV burden. Unlike high-income countries with advanced prevention care and early access to preventive solution, India still faces challenges in timely diagnosis and protection. Increased awareness around the severity of RSV and enabled access to ground-breaking immunization solutions will be critical in building a more equitable and effective national response to RSV.'
In April 2025, Sanofi and Dr. Reddy's announced the expansion of their partnership to bring to India a novel, single-dose preventive immunization developed to protect infants from RSV-related complications. Caregivers or parents are advised to speak with their pediatricians / neonatologist for more details.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
2 hours ago
- Hans India
Over 14 mn children worldwide did not receive a single vaccine in 2024: UN
New Delhi: More than 14 million children worldwide did not receive a single dose of any vaccine in 2024, according to new national immunisation coverage data released on Tuesday by the UN agencies World Health Organization (WHO) and UNICEF. The report showed that nearly 20 million infants missed at least one dose of diphtheria, tetanus, and pertussis (DTP)-containing vaccine last year, threatening to unwind decades of progress. More than 30 million children also remained under-protected against measles, leading to more large or disruptive outbreaks. In 2024, the number of countries experiencing large or disruptive measles outbreaks rose sharply to 60, nearly doubling from 33 in 2022. The report blamed limited access to immunisation services, disrupted supply, conflict, and instability, or misinformation about vaccines for children remaining un or under-vaccinated. "Vaccines save lives, allowing individuals, families, communities, economies and nations to flourish," said WHO Director-General Dr. Tedros Adhanom Ghebreyesus. He noted that the missed doses were due to the 'drastic cuts in aid, coupled with misinformation about the safety of vaccines'. The report also noted that global childhood vaccination coverage held steady with around 171,000 more children receiving at least one vaccine compared to 2023, and one million more completed the full three-dose DTP series. In 2024, 89 per cent of infants globally -– about 115 million -– received at least one dose of the DTP-containing vaccine, and 85 per cent -- roughly 109 million – completed all three doses. Coverage against measles also improved, with 84 per cent of children receiving the first dose and 76 per cent receiving the second dose, which shows a slight increase from the previous year. An estimated 2 million more children were reached in 2024, but the overall coverage rate is far below the 95 per cent needed in every community to prevent outbreaks. 'The good news is that we have managed to reach more children with life-saving vaccines. But millions of children remain without protection against preventable diseases, and that should worry us all,' said UNICEF Executive Director Catherine Russell. Russell called on governments for increased determination "to overcome barriers like shrinking health budgets, fragile health systems along with misinformation and access constraints because of conflicts. No child should die from a disease we know how to prevent.' The report also raised concerns over falling national and global funding, growing instability worldwide, and rising vaccine misinformation that is threatening to further stall or even reverse progress made in the last several decades. This would risk increases in severe disease and deaths from vaccine-preventable diseases.
Time of India
3 hours ago
- Time of India
WHO recommends a twice-a-year injection for HIV prevention
The World Health Organization is now recommending that countries include a newly approved HIV drug for prevention, lenacapavir, as a tool in their efforts to fight HIV infections, especially for groups most at risk and in areas where the burden of HIV remains high. This landmark guidance, released at the 13th International AIDS Society Conference in Kigali on July 14 – as concern looms over funding for the global HIV fight – endorses the drug's use every six months, marking a pivotal shift from daily pills to long‑acting, needle‑delivered protection. What is Lenacapavir? Lenacapavir (brand names Sunlenca for treatment, Yeztugo for prevention) is a long‑acting capsid inhibitor that has redefined HIV prevention. Administered via injection just twice a year, it works by targeting the structural protein (capsid) of the HIV, blocking its ability to replicate in the body. Lenacapavir was approved in 2022 to treat certain HIV infections, and in trials for prevention, it was found to dramatically reduce the risk of infection and provide almost total protection against HIV. WHO's official recommendation Dr. Meg Doherty, director of WHO's Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, said in a news briefing, 'These new recommendations are designed for real-world use. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Is it legal? How to get Internet without paying a subscription? Techno Mag Learn More Undo WHO is working closely with countries and partners to support the implementation.' Doherty added, 'The first recommendation is that a long-acting injectable, lenacapavir, should be offered as an additional prevention choice for people at risk for HIV and as part of combination prevention. With that, we call it a strong recommendation with moderate to high certainty of the evidence.' The second recommendation in the guidelines is that rapid diagnostic tests, like at-home tests, can be used to screen someone for HIV when they are starting, continuing, or stopping long-acting medication to prevent infection, called pre-exposure prophylaxis, or PrEP. Health leaders, including WHO's Director‑General Dr. Tedros Adhanom Ghebreyesus, touted lenacapavir as 'the next best thing' to an HIV vaccine. This latest endorsement complements existing WHO‑approved prevention methods – daily oral PrEP, bi‑monthly cabotegravir injections, and the dapivirine vaginal ring. WHO also streamlined HIV testing protocols to support injectable PrEP uptake in community settings, pharmacies, and telehealth contexts. Why a twice‑yearly injection might prove to be a good shot Adherence and convenience: Daily pill demands consistency, which many at‑risk individuals struggle to maintain. Lenacapavir simplifies prevention to two clinic visits per year, helping sidestep barriers like stigma, pill fatigue, or limited healthcare access. Effectiveness: Purpose trial data speaks volumes: in one study, zero infections occurred among participants receiving lenacapavir, compared to significant infection rates in the pill‑based PrEP group. Equity and access: High‑risk populations – sex workers, LGBTQ+ individuals, people who inject drugs, incarcerated people, adolescents – stand to gain most from an easy‑to‑administer, long‑lasting prevention tool. What is HIV/AIDS? HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases. It is spread by contact with certain bodily fluids of a person with HIV, most commonly during unprotected sex (sex without a condom or HIV medicine to prevent or treat HIV), or through sharing injection drug equipment. If left untreated, HIV can lead to the disease AIDS (acquired immunodeficiency syndrome). Within a few weeks of HIV infection, flu-like symptoms such as fever, sore throat, and fatigue can occur. Then the disease is usually asymptomatic until it progresses to AIDS. AIDS symptoms include weight loss, fever or night sweats, fatigue, and recurrent infections. There is no existing cure for AIDS, but strict adherence to antiretroviral regimens (ARVs) can dramatically slow the disease's progress as well as prevent secondary infections and complications. Vaccines for HIV are under trial, but no effective vaccine has been developed to date. In early 2025, the global fight against HIV/AIDS faced a significant setback with the United States of America's decision to halt foreign aid funding for HIV prevention and treatment programs. This move, part of a broader 90-day pause in US foreign development assistance, sent shockwaves through the international health community only a week ago, raising alarms about a potential resurgence of the epidemic. WHO's endorsement of twice‑yearly lenacapavir marks a transformative moment, especially amidst the looming concerns regarding the funding cuts. Gilead Sciences, maker of lenacapavir, recently announced that it has reached an agreement with the nonprofit Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir for HIV prevention at no profit to the company. Under this agreement, Gilead's pricing reflects only the cost of producing and delivering lenacapavir. Gilead Chairman and CEO Daniel O'Day said in a news release, 'We are providing the medicine at no profit to Gilead, and in enough supply to reach up to two million people in low- and lower-middle-income countries ahead of generic lenacapavir becoming available.' Peter Sands, executive director of the Global Fund, said in the news release, lenacapavir can 'fundamentally change the trajectory of the HIV epidemic,' but only if it reaches the people who need it most. As per him, 'Our ambition is to reach 2 million people with long-acting PrEP. But we can only do that if the world steps up with the resources required. This is a pivotal moment — not just for the fight against HIV, but for the fundamental principle that lifesaving innovations must reach those who need them most — whoever they are, and wherever they live.' If scaled equitably and thoughtfully, this intervention could reshape the landscape of HIV prevention, moving us closer to a world without AIDS. Actor Nargis Fakhri Reveals 9‑Day Water Fast Twice a Year to Get 'Snatched'
Time of India
3 hours ago
- Time of India
UN says 14 million children did not receive a single vaccine in 2024
London: More than 14 million children did not receive a single vaccine last year - about the same number as the year before - according to UN health officials. Nine countries accounted for more than half of those unprotected children. In their annual estimate of global vaccine coverage , released Tuesday, the World Health Organization and UNICEF said about 89 per cent of children under one year old got a first dose of the diphtheria, tetanus and whooping cough vaccine in 2024, the same as in 2023. About 85 per cent completed the three-dose series, up from 84 per cent in 2023. Officials acknowledged, however, that the collapse of international aid this year will make it more difficult to reduce the number of unprotected children. In January, US President Trump withdrew the country from the WHO, froze nearly all humanitarian aid and later moved to close the US AID Agency. And last month, Health Secretary Robert F. Kennedy Jr. said it was pulling the billions of dollars the US had previously pledged to the vaccines alliance Gavi, saying the group had "ignored the science". Kennedy, a longtime vaccine skeptic, has previously raised questions the diphtheria, tetanus and whooping cough vaccine - which has proven to be safe and effective after years of study and real-world use. Vaccines prevent 3.5 million to 5 million deaths a year, according to UN estimates. "Drastic cuts in aid, coupled with misinformation about the safety of vaccines, threaten to unwind decades of progress," said WHO Director-General Tedros Adhanom Ghebreyesus. UN experts said that access to vaccines remained "deeply unequal" and that conflict and humanitarian crises quickly unraveled progress; Sudan had the lowest reported coverage against diphtheria, tetanus and whooping cough. The data showed that nine countries accounted for 52 per cent of all children who missed out on immunisations entirely: Nigeria, India, Sudan, Congo, Ethiopia, Indonesia, Yemen, Afghanistan and Angola. WHO and UNICEF said that coverage against measles rose slightly, with 76 per cent of children worldwide receiving both vaccine doses. But experts say measles vaccine rates need to reach 95 per cent to prevent outbreaks of the extremely contagious disease. WHO noted that 60 countries reported big measles outbreaks last year. The US is now having its worst measles outbreak in more than three decades, while the disease has also surged across Europe, with 1,25,000 cases in 2024 - twice as many as the previous year, according to WHO. Last week, British authorities reported a child died of measles in a Liverpool hospital. Health officials said that despite years of efforts to raise awareness, only about 84 per cent of children in the UK are protected. "It is hugely concerning, but not at all surprising, that we are continuing to see outbreaks of measles," said Helen Bradford, a professor of children's health at University College London. "The only way to stop measles spreading is with vaccination," she said in a statement. "It is never too late to be vaccinated - even as an adult."
